March 15th update: Version 8 ICGC data protal (updates)International Cancer Genome Consortium

International Cancer Genome Consortium

 ICGC Goal: To obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes which are of clinical and societal importance across the globe

• 15/March/2012 - The ICGC Data Coordination Center (DCC) is pleased to announce the release of Version 8 of the ICGC data portal.
  
  This update includes first data releases from France’s Liver Cancer project, Germany’s Pediatric Brain Cancer project, and the United Kingdom’s Myelodysplastic Syndrome Project. Also included are new submissions from the Australian Pancreatic Cancer project, the Canadian Pancreatic Cancer project, the Japanese Liver Cancer project, and the United Kingdom Breast Cancer (Triple Negative) project.
  
  This data adds to previous data releases from the Chinese Gastric Cancer project, the Spanish Chronic Lymphocytic Leukemia project and submissions from The Cancer Genome Atlas in the United States, which has contributed information on about 10 types of cancer affecting the blood, brain, breast, colon, kidney, lung, ovaries, rectum, stomach and uterus.
  
  In total, 600 newly-available cancer datasets are provided in this release, with the ICGC data portal now containing data from 3,561 cancer genomes.

Updates

• Currently, the ICGC has received commitments from funding organizations in Asia, Australia, Europe and North America for 47 project teams in 15 jurisdictions to study over 21,000 tumor genomes. Projects that are currently funded are examining tumors affecting the bladder, blood, bone, brain, breast, cervix, colon, head and neck, kidney, liver, lung, oral cavity, ovary, pancreas, prostate, rectum, skin, soft tissues, stomach, thyroid and uterus. Over time, additional nations and organizations are anticipated to join the ICGC. The genomic analyses of tumors conducted by ICGC members in Australia and Canada (pancreatic cancer), China (gastric cancer), France (liver cancer), Germany (brain cancer), Japan (liver cancer), Spain (blood cancer), the UK (blood, breast, lung and skin cancer) and the USA (blood, brain, breast, colon, kidney, lung, ovarian, rectal, stomach and uterine cancer) are now available through the Data Coordination Center housed on the ICGC website at www.icgc.org.

ICGC Releases New Genomic Data on Cancer Ahead of Schedule -- TORONTO, July 11, 2011 /PRNewswire/ --

"...The data include new submissions to the ICGC from The Cancer Genome Atlas (TCGA) in the United States, which has contributed information on about 10 types of cancer affecting the blood, brain, colon, kidney, lung, ovaries, rectum, and uterus, including data from a study of 500 ovarian cancer patients published in the journal Nature on June 30......

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.
The ICGC also announced that new projects in Italy and the European Union will contribute to efforts already underway in Australia, Canada, China, France, Germany, India, Japan, Spain, the United Kingdom, and the United States. As the UK's arm of the ICGC, the Wellcome Trust Sanger Institute will decode hundreds of breast cancer genomes as part of the Consortium's international efforts.
Other funded projects will examine more than 10,000 tumours for cancer types that affect organs including blood, brain, breast, colon, kidney, liver, lung, pancreas, stomach, oral cavity and ovary.
The paper, by over 200 authors participating in ICGC projects, is published today in the journal Nature. The paper describes how the projects will proceed, outlining the ethical framework, study design and policies. ICGC leaders will also present progress on their projects at the annual conference of the American Association for Cancer Research in Washington DC, 17 - 21 April, 2010.